Vapotherm Inc.

107 Ridgely Avenue
Suite 9
Annapolis
Maryland
21401
United States

Tel: 410-974-9255
Fax: 410-974-9707

Email: INFO@VTHERM.COM

Show jobs for this employer

82 articles with Vapotherm Inc.

  • Vapotherm, Inc. today announced that its management team will be hosting their first investor day on Wednesday, June 23, 2021 beginning at 10:00AM ET.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the Bank of America Securities 2021 Health Care Conference on Wednesday, May 12, 2021 via webcast.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, announced first quarter 2021 financial results.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Wednesday, May 5, 2021.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in a Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science Conference

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2020 after the close of trading on Wednesday, February 24, 2021.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.

  • Vapotherm to Present at the 23 rd Annual ICR/Westwicke Conference

  • Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® systems, has been awarded the prestigious American Association for Respiratory Care Zenith Award.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced third quarter 2020 financial results.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committ

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it has entered into a loan and security agreement with CIBC Innovation Banking that provides the Company with up to $52 million in debt financing through a combination of a term loan facility and a revolving credit facility

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 4, 2020

  • Vapotherm, Inc. announced the release of a low-cost, easy to use kit to help clinicians create a zone of relative negative pressure at the patient's face which may mitigate the risk of transmission of potentially infectious particles while treating COVID-19 patients.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 via webcast.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2020 financial results.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2020 after the close of trading on Tuesday, August 4, 2020.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, announced a major expansion in its capital equipment manufacturing capabilities.